Vyriad, a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, has announced the closing of the $25 million final tranche to its Series B financing, bringing the total Series B round to $85 million. This additional funding supports the imminent first-in-human testing of VV169, Vyriad's in vivo CAR-T candidate, in patients with relapsed or treatment-refractory multiple myeloma..

临床阶段生物技术公司 Vyriad 致力于开发针对癌症和其他严重疾病的靶向基因疗法，近日宣布完成了 2500 万美元的 B 轮融资最终部分，使得此轮融资总额达到 8500 万美元。这笔额外的资金将用于支持 Vyriad 的体内 CAR-T 候选药物 VV169 即将在复发或治疗难治性多发性骨髓瘤患者中进行的首次人体试验。

The Series B, including this latest tranche, was led by Mr. Harry Stine of Stine Seed Farms, Inc., the world's largest private seed company and a technology leader in plant genetics. Several significant family offices also participated.

包括这一最新部分在内的 B 轮融资由世界上最大的私人种子公司、植物遗传学技术领导者 Stine Seed Farms, Inc. 的 Harry Stine 先生领投，数家重要的家族办公室也参与其中。

Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells. It has ongoing corporate partnerships with Regeneron Pharmaceuticals and Novartis.

Vyriad 是一家临床阶段的生物技术公司，致力于开发针对癌症和其他严重疾病的靶向基因药物。该公司利用工程病毒、病毒载体和病毒包膜糖蛋白将治疗基因直接递送到选定的细胞中。Vyriad 与再生元制药（Regeneron Pharmaceuticals）和诺华（Novartis）保持着持续的企业合作关系。

Vyriad's developmental programs include oncolytic virotherapy, in vivo gene therapy, and gene-editing applications, with ongoing Phase 1-2 trials across multiple cancer indications. Vyriad is a privately held company based in Rochester, Minnesota and was co-founded by Mayo Clinician-Scientists, Dr. Stephen Russell and Dr.

Vyriad 的开发项目包括溶瘤病毒疗法、体内基因治疗和基因编辑应用，目前正在进行涵盖多种癌症适应症的 1-2 期临床试验。Vyriad 是一家私人控股公司，总部位于明尼苏达州罗切斯特，由梅奥诊所的科学家兼医生 Stephen Russell 博士和另一位科学家共同创立。

Kah-Whye Peng, to further develop and bring into clinical trials a set of research breakthroughs in their gene and virus therapy research labs..

彭嘉辉，为了进一步开发并将其基因和病毒治疗研究实验室的一系列研究突破带入临床试验。